Join the Oncology Voice Network. Join for Free
Bringing the Patient Voice into Company-Sponsored Publications: The Med Comms Perspective
patient participation in scientific publishing medical communications and patient engagement roles of patients in research communicating with patient advocates patient education in research patient engagement podcast scientific publishing process

Bringing the Patient Voice into Company-Sponsored Publications: The Med Comms Perspective


Share This Article


Summary

Continuing our look at increasing patient participation in the scientific publication process, this episode of InformED will look at the process from a medical communications perspective. Our guests discuss questions to think through during the planning stages including: the different roles that patients can take, how to best communicate with patients and patient advocates, and education they may need to fully engage in the process.

Guest host Kelly Soldavin, Senior Editor at Taylor & Francis Group is joined by Jacqui Oliver, Patient Partnership Director, Scientific at Envision Pharma Group and Sarah Griffiths, Communications Director, Patient Engagement at Oxford PharmaGenesis to for this second episode in a series of patient engagement in scientific publishing podcasts.

Click for Source
patient participation in scientific publishing, medical communications and patient engagement, roles of patients in research, communicating with patient advocates, patient education in research, patient engagement podcast, scientific publishing process

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Real-World Evidence in Oncology: Opportunities and Limitations
OVN Avatar Massimo Di Maio, Francesco Perrone, Pierfranco Conte

Real-World Evidence in Oncology: Opportunities and Limitations

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Accelerated drug approvals in oncology: Pros and cons
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
OVN Avatar Laleh Amiri-Kordestani & Richard Pazdur

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN